These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23000876)

  • 21. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
    Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
    Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New histopathologic findings in drug eruptions.
    Fitzpatrick JE
    Dermatol Clin; 1992 Jan; 10(1):19-36. PubMed ID: 1530913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.
    Balagula Y; Garbe C; Myskowski PL; Hauschild A; Rapoport BL; Boers-Doets CB; Lacouture ME
    Int J Dermatol; 2011 Feb; 50(2):129-46. PubMed ID: 21244375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
    Tan EH; Chan A
    Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eosinophilic Infiltrates in Vemurafenib-Associated Verrucous Keratoses.
    Longhurst WD; Honda K; Koon HB; Gerstenblith MR
    Am J Dermatopathol; 2016 Oct; 38(10):766-8. PubMed ID: 27533075
    [No Abstract]   [Full Text] [Related]  

  • 26. Three cases of toxic skin eruptions associated with methotrexate and a compilation of methotrexate-induced skin eruptions.
    Scheinfeld N
    Dermatol Online J; 2006 Dec; 12(7):15. PubMed ID: 17459301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging adverse cutaneous drug reactions.
    Hagen JW; Magro CM; Crowson AN
    Dermatol Clin; 2012 Oct; 30(4):695-730, vii. PubMed ID: 23021055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib: atypical cutaneous side effects.
    Richetta AG; Maiani E; Carboni V; Carlomagno V; Cimillo M; Mattozzi C; Calvieri S
    Eur J Dermatol; 2007; 17(6):549-50. PubMed ID: 17951148
    [No Abstract]   [Full Text] [Related]  

  • 29. Cutaneous reactions to epidermal growth factor receptor inhibitors.
    Pomerantz RG; Mirvish ED; Geskin LJ
    J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morbilliform drug reaction with histologic features of pustular dermatosis associated with bryostatin-1.
    Krejci-Manwaring JM; Bogle MA; Diwan HA; Duvic MA
    J Drugs Dermatol; 2003 Oct; 2(5):557-61. PubMed ID: 14558406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.
    Nikolaou V; Voudouri D; Tsironis G; Charpidou A; Stamoulis G; Triantafyllopoulou I; Panoutsopoulou I; Xidakis E; Bamias A; Samantas E; Aravantinos G; Gogas H; Rigopoulos D; Syrigos K; Stratigos A
    Support Care Cancer; 2019 Dec; 27(12):4535-4542. PubMed ID: 30919155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J; Escudier B; Wechsler J; Spatz A; Robert C
    Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histopathologic reactions to chemotherapeutic agents.
    Fitzpatrick JE; Hood AF
    Adv Dermatol; 1988; 3():161-83. PubMed ID: 2978953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
    Lacouture ME; Desai A; Soltani K; Petronic-Rosic V; Laumann AE; Ratain MJ; Stadler WM
    Clin Exp Dermatol; 2006 Nov; 31(6):783-5. PubMed ID: 16824050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors.
    Lupu I; Voiculescu VM; Bacalbasa N; Prie BE; Cojocaru I; Giurcaneanu C
    J Med Life; 2015; 8 Spec Issue(Spec Issue):57-61. PubMed ID: 26361513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug eruptions associated with tumor therapy: Great imitators.
    Ludwig C; Goh V; Rajkumar J; Au J; Tsoukas M
    Clin Dermatol; 2020; 38(2):208-215. PubMed ID: 32513400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous Reactions to Targeted Therapy.
    Lee JJ; Kroshinsky D; Hoang MP
    Am J Dermatopathol; 2017 Feb; 39(2):67-82. PubMed ID: 28134724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse cutaneous reactions to chemotherapeutic drugs.
    Haynes D; Ortega-Loayza AG
    Clin Dermatol; 2020; 38(6):712-728. PubMed ID: 33341204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cutaneous Adverse Reactions of Anticancer Agents.
    Kaul S; Kaffenberger BH; Choi JN; Kwatra SG
    Dermatol Clin; 2019 Oct; 37(4):555-568. PubMed ID: 31466595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cutaneous side effects of targeted cancer drugs].
    Below J; Homey B; Gerber PA
    Hautarzt; 2017 Jan; 68(1):12-18. PubMed ID: 27885401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.